LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Listă Acțiuni・Incyte Corp

Incyte Corp

Închisă

SectorSănătate

105.37 2.11

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

102.36

Maxim

110.19

Indicatori cheie
By Trading Economics
Venit	4.1M 303M
Vânzări	-234M 1.3B
P/E Medie Sector	14.215 49.052
EPS	1.81
Marjă de profit	23.834
Angajați	2,844
EBITDA	-47M 368M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+6.93% upside

Dividende
By Dow Jones
Următoarele câștiguri	28 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	1.1B 20B
Deschiderea anterioară	103.26
Închiderea anterioară	105.37

Sentimentul știrilor

By Acuity

32%

68%

81 / 344 Clasament în Healthcare

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 iun. 2026, 23:36 UTC

Câștiguri

Correction to Oracle Reports Higher 4Q Profit Article

10 iun. 2026, 23:19 UTC

Acțiuni populare

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 iun. 2026, 23:09 UTC

Principalele dinamici ale pieței

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 iun. 2026, 23:04 UTC

Câștiguri

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 iun. 2026, 20:44 UTC

Principalele dinamici ale pieței

Caterpillar Raises Quarterly Dividend 8%

10 iun. 2026, 23:49 UTC

Achiziții, Fuziuni, Preluări

Elliott: Northern Star Should Take No Options Off The Table

10 iun. 2026, 23:48 UTC

Achiziții, Fuziuni, Preluări

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 iun. 2026, 23:48 UTC

Achiziții, Fuziuni, Preluări

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 iun. 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 iun. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 iun. 2026, 23:46 UTC

Achiziții, Fuziuni, Preluări

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 iun. 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

10 iun. 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 iun. 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 iun. 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 iun. 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 iun. 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

10 iun. 2026, 21:57 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:52 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:35 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 21:22 UTC

Câștiguri

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 iun. 2026, 20:50 UTC

Market Talk

Câștiguri

Tech, Media & Telecom Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 iun. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 iun. 2026, 20:39 UTC

Market Talk

Câștiguri

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 iun. 2026, 20:34 UTC

Câștiguri

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 iun. 2026, 20:33 UTC

Câștiguri

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 iun. 2026, 20:33 UTC

Market Talk

Câștiguri

Global Equities Roundup: Market Talk

10 iun. 2026, 20:33 UTC

Market Talk

Câștiguri

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

6.93% sus

Prognoză pe 12 luni

Medie 110.38 USD 6.93%

Maxim 140 USD

Minim 75 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

19 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 19 analiști care au acordat evaluări ale acțiunilor Incyte Corp - Dist în ultimele 3 luni.

Sentiment

By Acuity

81 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation